Related Experiment Video
Updated: May 30, 2026

Using Micro-Electro-Mechanical Systems (MEMS) to Develop Diagnostic Tools
Published on: October 1, 2007
Biomedical innovation: a risky business at risk
Richard S Stack1, Robert A Harrington
1SyneCor, Chapel Hill, NC 27517, USA. rstack@synecor.com
Abstract:
Regulatory and financial challenges conspire to stall the development and market approval of breakthrough medical products. Inconsistent parameters are used to assess the safety and efficacy of drugs, biologics, and devices; this glitch in the system introduces uncertainty, slows or blocks product approvals, and increases the costs of product development. Here, we consider how to balance the benefits and risks to the public in the assessment of innovative medical products. We also discuss the Institute of Medicine's recent report on the medical device approval process.
Related Concept Videos
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Products: Biologics, Biosimilars and Interchangeables
Microorganisms in Medicine and Therapeutics
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bacterial Signaling

